BioAge Labs, Inc. (BIOA) Financial Statements
BioAge Labs, Inc. (BIOA) reported trailing twelve-month revenue of $10.4M (up 168.1% year on year) and net income of -$94.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$88.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BIOABioAge Labs, Inc.Follow BIOA — free
—
Price chart with a free account
- Market cap
- 234.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|
| Revenue | 9.0 | 10.4 | |
| Research & development | 74.0 | 87.8 | |
| Operating income | -92.8 | -106.3 | |
| Pre-tax income | -80.6 | -94.5 | |
| Income tax | 0.0 | — | |
| Net income | -80.6 | -94.5 | |
| Diluted EPS ($) | -2.24 | -2.10 | |
| Diluted shares (mn) | 35.9 | — |
USD millions · SEC XBRL
BioAge Labs, Inc. — questions
- What is BioAge Labs, Inc.'s revenue?
- $10.4M over the twelve months to 2026-06-30, up 168.1% year on year, from its 10-Q and 10-K filings.
- What is BioAge Labs, Inc.'s net income?
- -$94.5M over the twelve months to 2026-06-30.
- What is BioAge Labs, Inc.'s free cash flow?
- -$88.1M over the twelve months to 2026-06-30.
- What are BioAge Labs, Inc.'s diluted earnings per share?
- $-2.10 over the twelve months to 2026-06-30.
Every figure on this page comes from BioAge Labs, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.